k13 Resistance Markers Hit 62% in Rwanda as East Africa Maps Show Artemisinin Partial Resistance Now Endemic

The study compiled published surveys across 47 African countries and generated high-resolution prevalence maps for validated k13 mutations. Partial resistance is now established across most of Uganda and Rwanda and the Ethiopia-Eritrea-Sudan border, patterns that replicate the early geographic expansion seen in Southeast Asia before ACT clinical failure became widespread. Absolute prevalence increases were largest in northern Rwanda and western Uganda, where modeled yearly gains exceeded 5 percentage points after 2018.

These genetic markers blunt artemisinin's rapid clearance effect but do not yet equate to full ACT failure because partner drugs still provide protection. However, historical data from the Thai-Cambodian border show that once k13 prevalence exceeds 50-60%, partner-drug resistance often follows within 3-5 years, raising the probability of outright treatment failure. The Imperial analysis therefore functions as an early-warning system rather than a direct measure of clinical outcomes.

Wider context reveals this is the latest instance of antimicrobial pressure selecting for resistance after successful scale-up of a single drug class. East African surveillance gaps remain large; only 12 countries contributed longitudinal data sufficient for modeling. Strengthened molecular networks and diversified treatment strategies are required before resistance translates into excess mortality.